(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Russia downs 16 drones heading for Moscow, mayor says - 2National health ranking puts Georgia near bottom of list. Here's why
- 3Well known SUVs With Low Energy Utilization In 2024 vote
- 4Shipping: The Corridors of Trade and the Coming of Another Period
- 5What to watch for as NASA’s historic Artemis II crew prepares to lift off toward the moon
- Figure out How to Protect Your Gold Venture from Unpredictability
- A trip to Colombia in my 20s turned into 8 years freelancing in South America. Here's what I'd do differently.
- Rick Steves' Favorite Time To Visit Spain Has Lower Prices And Fewer Crowds
- Vote In favor of Your Number one Cell phones
- Birutė Galdikas: The last of the ‘angels’ in primatology’s most extraordinary chapter
- Individual Preparation Administrations to Raise Your Wellness Process
- The hunt for dark matter: a trivia quiz
- This Miraculous, Cliff-Perched Town In The South Of France Is A Sacred European Gem
- Artemis 2 moon astronauts will try to recreate Apollo 8's historic 'Earthrise' photo during April 6 flyby
